Radiculopathy

Orthofix Announces Publication in The Spine Journal of Five-Year Data for the M6-C Artificial Cervical Disc

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Physical Therapy, Surgery, Health, FDA, Medical Devices, Clinical Trials, Other Health, Principal, Food and Drug Administration, Neck, SSI, Orthopedic surgery, Safety, Food, Radiculopathy, Spine, Clinical trial, Patient, Multimedia, ACDF, The Spine Journal, IDE, SAE, Trial of the century, Rush University Medical Center, Pain, Medical device

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the publication of the five-year results from the U.S. clinical study comparing the M6-C™ artificial cervical disc with anterior cervical discectomy and fusion (ACDF).

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the publication of the five-year results from the U.S. clinical study comparing the M6-C™ artificial cervical disc with anterior cervical discectomy and fusion (ACDF).
  • Published in The Spine Journal , patients treated with the M6-C disc demonstrated superior clinical success at 60 months compared to ACDF patients.
  • View the full release here: https://www.businesswire.com/news/home/20231129606400/en/
    The Orthofix M6-C™ artificial cervical disc is a next-generation artificial disc developed to replace an intervertebral disc damaged by cervical disc degeneration.
  • “Artificial cervical disc replacement is becoming the gold standard of care for indicated patients who may otherwise be facing cervical disc fusion.

DISC Surgery Center at Newport Beach Now Enrolling Patients in Clinical Study on Artificial Disc Replacement

Retrieved on: 
Tuesday, November 28, 2023
Health, Research, Safety, Patient, DISC, Motion, Radiculopathy, ACDF, Trial of the century, FDA, Nursing, DRS

NEWPORT BEACH, Calif., Nov. 28, 2023 /PRNewswire/ --Committed to supporting research vital to the field of spinal care, DISC Surgery Center at Newport Beach ("DISC") has announced its participation in a clinical study on artificial disc replacement and is now enrolling qualified patients. Candidates may include patients between the ages of 18 and 75 who have been told they need cervical (neck) surgery at two consecutive levels (among other requirements).

Key Points: 
  • NEWPORT BEACH, Calif., Nov. 28, 2023 /PRNewswire/ --Committed to supporting research vital to the field of spinal care, DISC Surgery Center at Newport Beach ("DISC") has announced its participation in a clinical study on artificial disc replacement and is now enrolling qualified patients.
  • Artificial disc replacement surgery is very similar to ACDF surgery.
  • However, when the deteriorated disc is removed for disc replacement, the space in between the vertebrae is filled with a specialized implant called an artificial disc, instead of a bone graft.
  • "The DISC Surgery Center at Newport Beach has put in over 3,000 cervical artificial discs since 2018, and we are well-versed in the surgery's motion-preservation qualities," said Dr. Mesiwala.

Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
FDA, Surgery, Medical Devices, Health, Clinical Trials, Abstract, Risk, Arm, Hip, PEMF, Radiculopathy, Diabetes, Osteoporosis, Trinity, Convention, VAS, Multimedia, Research, Neck, SF-36, National Primate Research Exhibition Hall, Osteolysis, IDE, Nonunion, NDI, International Society, Birth control, Medical device, Patient

View the full release here: https://www.businesswire.com/news/home/20230601005376/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230601005376/en/
    Illustration of the Orthofix M6-C artificial cervical disc.
  • (Graphic: Business Wire)
    “We are pleased to support a wide range of abstracts and clinical data during the annual ISASS meeting, including the first presentation of the seven-year data from the M6-C artificial cervical disc U.S. IDE study,” said Kevin Kenny, President of Global Spine.
  • “M6-C Artificial Cervical Disc: Seven-Year Outcomes for Single-Level Total Disc Replacement with a Novel Viscoelastic Artificial Cervical Disc” – abstract presentation by Dr. Todd Lanman.
  • This abstract is the first public presentation of specific seven-year clinical results associated with the use of the M6-C artificial cervical disc for the treatment of single-level symptomatic cervical radiculopathy.

Locate Bio’s LDGraft Granted FDA Breakthrough Device Designation

Retrieved on: 
Thursday, May 18, 2023
Medical Devices, FDA, Health, Surgery, Pharmaceutical, Biotechnology, Spinal fusion, Surgeon, Low back pain, Bio, Degenerative disc disease, Disability, Myelopathy, Quality of life, Bone morphogenetic protein 2, Spinal disc herniation, Radiculopathy, Patient, DDD, Diagnosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Spinal stenosis, Pharmaceutical industry, Locate

Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.

Key Points: 
  • Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.
  • The FDA Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
  • We are delighted therefore to have been granted a Breakthrough Device designation from the FDA for LDGraft, our exciting controlled and extended-release rhBMP-2 for spinal fusion.
  • We are proud that the FDA has recognised the potential of LDGraft.

Chiropractic May Offer Relief From Complicated Chronic Headaches

Retrieved on: 
Monday, November 21, 2022
Tao, Signs and symptoms, Report, Postural orthostatic tachycardia syndrome, Pathology, Sensation, Neck, Neck pain, Pectus carinatum, Neurofibromatosis, Chronic pain, Pain scale, Lactic acid, History, Chiropractic, Foramen magnum, Spine, ECP, Multimedia, Dizziness, Patient, Head, Executive Committee, Bell's palsy, Radiculopathy, Academy of Family Physicians of India, Literature review, CRP, Dentistry, Poultry, Birth control, Healthcare, Online shopping, Headache

NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.

Key Points: 
  • The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.
  • Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong.
  • "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches.
  • Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”

Retrieved on: 
Thursday, November 10, 2022
Quality of life, Fibromyalgia, GLOBE, Private Securities Litigation Reform Act, Nasdaq, Business architecture, TRPV1, Forward-looking statement, Vaccine, PHN, Radiculopathy, NCT, USP, Food, Risk, Population, PALO, RTX, Dexamethasone, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Fast track (FDA), Therapy, Phase, SEC, Chronic pain, Failure, SP-102, Antibody, Sciatica, Time, Cancer, Company, Postherpetic neuralgia, Capsule, Patient, Pain, Growth, Low back pain, SP-104, Physician, Autoimmune disease, Acquisition, Osteoarthritis, FDA, Television, Management, Pharmaceutical industry

The combined company now operates as Scilex Holding Company.

Key Points: 
  • The combined company now operates as Scilex Holding Company.
  • Ringing the opening bell at Nasdaq is indicative of our teams hard work and celebration of our continued growth, said Henry Ji, Ph.D.
  • Scilex Holding Company will ring the Nasdaq opening bell at 9:30 a.m.
  • Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination

Retrieved on: 
Thursday, November 10, 2022
PHN, Partnership, Risk, Population, Therapy, Chronic pain, Company, Postherpetic neuralgia, SP-104, Autoimmune disease, Quality of life, Forward-looking statement, USP, Food, RTX, SEC, Sciatica, Time, Cancer, Capsule, Patient, Acquisition, Osteoarthritis, COVID-19, Business architecture, Private Securities Litigation Reform Act, Leadership, Vaccine, Nasdaq, Regulation of tobacco by the U.S. Food and Drug Administration, Fast track (FDA), Phase, Antibody, Low back pain, Physician, Cayman, Business, FDA, GLOBE, Fibromyalgia, TRPV1, Radiculopathy, NCT, PALO, LLP, Dexamethasone, Failure, SP-102, Pain, NEW, Security (finance), Pharmaceutical industry

Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination.

Key Points: 
  • Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination.
  • I, a special purpose acquisition company, today announced the closing of their previously announced business combination (the "Business Combination").
  • We appreciate our partnership with the team at Vickers as we prepare for this next chapter.
  • Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California.

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes

Retrieved on: 
Thursday, September 29, 2022
Postherpetic neuralgia, Patient, Combination company, Physician, Nasdaq, Note, NCT, PALO, RTX, Time, SP-104, Autoimmune disease, COVID-19, Sale, Food, Securities Act of 1933, Antibody, Company, Fibromyalgia, Acquisition, BCA, Osteoarthritis, Pain, Fast track (FDA), SAN, Sciatica, Prospectus, SEC, Failure, Registration statement, Risk, FDA, Phase, Population, SP-102, Forward-looking statement, Vaccine, GLOBE, Proxy, Dexamethasone, Low back pain, Register, PHN, Name, TRPV1, Private Securities Litigation Reform Act, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Quality of life, Radiculopathy, Combined, Form, Capsule, Chronic pain, USP, Pharmaceutical industry, Security (finance)

Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento).

Key Points: 
  • Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento).
  • The boards of directors of each of Vickers, Scilex and Sorrento have unanimously approved the proposed transaction.
  • Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.
  • Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California.

Synergy Spine Solutions and Ortho Consulting Group extend strategic partnership to commercialize innovative spine technologies

Retrieved on: 
Monday, September 12, 2022
Vision, IDE, Growth, Synergy, Partnership, Patient, Thought, DDD, Marquess, Technology, SME, Quality of life, Standard of care, Spine, EMEA, Leadership, Solution, OCG, Surgeon, Motion, Marketing, Education, Radiculopathy, Myelopathy, Fine chemical, Renewable energy

NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions (Synergy) has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.

Key Points: 
  • NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions(Synergy)has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.
  • The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care.
  • In the United States,the Synergy Disc is investigational use only andSynergy is currently enrolling patients in its IDE study.
  • For more information, visit synergyspinesolutions.com
    Ortho Consulting Group helps companies within the orthopaedic and spine industry build and strengthen their global sales channels.

Synergy Spine Solutions and Ortho Consulting Group extend strategic partnership to commercialize innovative spine technologies

Retrieved on: 
Monday, September 12, 2022
Vision, IDE, Growth, Synergy, Partnership, Patient, Thought, DDD, Marquess, Technology, SME, Quality of life, Standard of care, Spine, EMEA, Leadership, Solution, OCG, Surgeon, Motion, Marketing, Education, Radiculopathy, Myelopathy, Fine chemical, Renewable energy

NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions (Synergy) has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.

Key Points: 
  • NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions(Synergy)has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.
  • The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care.
  • In the United States,the Synergy Disc is investigational use only andSynergy is currently enrolling patients in its IDE study.
  • For more information, visit synergyspinesolutions.com
    Ortho Consulting Group helps companies within the orthopaedic and spine industry build and strengthen their global sales channels.